Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Andy Plump

Andy Plump

President of R&D, Takeda

Appears in 1 story

Notable Quotes

"The level of efficacy that we're seeing, combined with the safety profile (and) with the convenience of administration, is quite unique in this landscape." — Andy Plump, Reuters

"[Takeda] has aspirations to enable all drug discovery and drug development with AI." — Andy Plump, Reuters

Stories

Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance

New Capabilities

Leading regulatory push and broader immunology expansion strategy

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated Yesterday